Danish biotech company Genmab (OMX: GEN) has reached a new milestone in its daratumumab collaboration with Janssen, the Europe-based subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ).
The progress of the Phase II study of daratumumab in non-Hodgkin’s lymphoma (NHL) has unlocked the second milestone payment, a sum of $5 million.
This study is an evaluation of daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze